Join us at Health Research Day — June 6th at Canton Waterfront Park, Baltimore!   Learn More →
← Back to all trials
Completed NCT05164705

Improving Human Cerebrovascular Function Using Acute Intermittent Hypoxia

Conditions: Healthy Brain Perfusion

Sex: All
Ages: 21 Years – 50 Years
Healthy volunteers: Yes
Phase: NA
Enrollment: 33
Sponsor: Northwestern University

Location: Northwestern University Chicago Illinois

Summary

This study uses magnetic resonance imaging to determine whether 3 weeks of repeated exposure to Acute Intermittent Hypoxia can improve brain blood flow or blood flow regulation in healthy adults.

Eligibility Criteria

Inclusion Criteria: * Healthy volunteers between ages of 21 and 50 years * No known neurological, respiratory or vascular conditions * Safe to be scanned using MRI * Able to communicate in English Exclusion Criteria: * MRI contraindications as indicated on MRI safety screening form * Subjects with pacemakers, cochlear (in the ear) implants, or aneurysm clips or subjects who have worked with metal * Pregnant women * Individuals with known neurological or vascular conditions * Individuals with sleep apnea, emphysema, or other respiratory conditions * Individuals with severe claustrophobia * Subjects unwilling or unable to give written informed consent in English * Prisoners * Frequent smoker * Allergy to Tegaderm * Blood pressure greater than 140/90 or less than 90/55. * Individuals who report headaches, feeling dizzy or light-headed, or have heart palpitations on the day of the study. * Individuals prescribed Aripiprazole and/or Lamotrigine\* Note, mild (well-controlled) asthma is not immediate grounds for exclusion. \*Other prescription medications may be grounds for exclusion; prescription medication information will be acquired during initial screening and at subsequent follow-up visits

Interested in this study? View the official listing for contact and enrollment details.

View on ClinicalTrials.gov

Source: ClinicalTrials.gov (NCT05164705). StuddyBuddy aggregates publicly available trial information.